StockGuru.com » StockGuru

Medizone International, Inc. (OTCBB: MZEI) New Message from Chairman Addresses Recent Issues

StockGuru — Thu, 11 Mar 2010 16:19:38 +0000

Chairman’s Message
Shareholder Update

March 11, 2010

It has been brought to my attention by shareholders there has recently been some misunderstanding as to development path timeframes for AsepticSure™. This message is intended to hopefully clear up those perceived misunderstandings.

The end of 2008 and going into early 2009 the company believed it would finalize product development by the end of 2009 with first deliveries during the first quarter of 2010. That has obviously proven to be an overly optimistic time frame, and I accept responsibility for not being more conservative with our projections at that time. Those projections were based on statements made to me by our development partner that the prototype equipment being planned for full-scale room treatment “would be very close to a production prototype.” This clearly has not proven to be the case.

As projects like this involving revolutionary technology and break through science evolve, they do have a tendency to take on a life of their own. Relative to the development of the room scale prototype, initially our development partner fell behind expectations relative to delivery time. Also, and this is a very big positive, on January 5, 2010 we announced “Test results achieved over the past two months now predictably demonstrate greater than 6 logs of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for Anthrax, Bacillus subtilis.” Those first 6-log results were achieved in our laboratory unit with technology that had not yet been integrated into our full-scale equipment. This incredible scientific accomplishment was explained in the January 10, 2010 press release relating to greatly enhanced patent protection. “This was made possible”, commented Dr Michael Shannon, Medizone’s Director of Medical Affairs, “through the integration of several complimentary technologies, each with their own antimicrobial effects, which in combination were shown not to be additive, but multiplicative.”

In sum, the goal posts had moved. Additional technologies that greatly enhanced the AsepticSure™ product now had to be integrated into a design that had not originally been considered for this additional technology that greatly enhanced efficacy. Thus, in reality, what was once intended to be “very close to a production prototype,” had clearly become a development machine that required additional engineering prior to being ready for hospital beta testing and production. During the last half of 2009, I tried to soften expectations relative to commercialization time frames in both how press releases were drafted and also with our SEC Filings. I hope this communication will clear up once and for all any misunderstanding.

Currently, utilizing an expanded and enhanced design team that is experienced in bringing products from the research stage to full production, Medizone is finalizing the design of a new, fully integrated AsepticSure™ system for hospital beta testing. This design will achieve the same results as the current beta prototype while also being a major step forward and very close to what we expect the full production prototype will be. Shareholders must comprehend, now that we understand the science and clearly understand what is required for open space sterilization such as in hospital settings, it is absolutely essential to deliver a product into the hospital beta test environment that maintenance staff within the hospital can easily be taught to use and the equipment must be 100% reliable. Anything short of that is a recipe for failure. Medizone Management from top to bottom and all of our development staff, are dedicated to that outcome; deliver a first rate, reliable machine, that hospitals can count on. Nothing less will do.

Since I want to be cautious with time frames given past slippages, hospital beta testing is expected to begin by late spring at sites in both the US and Canada. Production developments from the hospital beta system are not expected to be in the hardware or basic design, but more related to things like state of the art packaging. However, let me caution, as I stated earlier in this communication, these things do have a way of taking on a life of their own.

We believe moving from hospital beta testing to initial production and sales at modest rates should prove to be a smooth, manageable transition. We expect sales should flow smoothly out of a successful beta test program. In closing, I think it is important for shareholders to remember that Medizone has achieved results in both laboratory and room scale trials that are absolutely unheard of in the scientific and medical communities. We expect the same success in commercialization.

We are still a small company with limited resources. I am proud of what we have achieved. It is absolutely essential that we not rush this next phase of product development, as it must be done correctly the first time. I assure you both Dr Shannon, myself and all of our team, are putting our full effort into making sure that is the case.

As we successfully transition into hospital beta testing, when the first peer reviewed journal article is published (expected this summer), as partners are announced and the management team and board are expanded to reflect the skill sets of a rapidly growing commercially viable company, our contribution to science and medicine will be clear to all.

Yours truly,

Edwin G. Marshall
Chairman &
CEO Medizone International, Inc.

This Chairman’s message contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

NXT Nutritionals Holdings, Inc. (OTCBB: NXTH) Susta™ Savvy Media and Marketing

StockGuru — Thu, 11 Mar 2010 14:52:07 +0000

(OTCBB: NXTH)

Talk about Media Savvy — this company gets it. Not ONLY with the celebrity endorsements but with an incredible internet campaign.

National Celebrities focused on fitness have endorsed NXTH.

Shaquille O’Neal, National Basketball Association star, Eddie George and Blair Underwood Public Face of Susta™ and NXT Nutritional Holdings, Inc.

Shaquille O’Neal will be a spokesman for NXT Nutritionals to educate children and adults about how SUSTA™ Natural Sweetener can help them curb the country’s growing epidemic of obesity and diabetes and increase market awareness of the SUSTA brand. O’Neal is a 15-time NBA All-Star, 4-time World Champion, 3 time NBA Finals MVP and is currently playing for the Cleveland Cavaliers.

O’Neal stated his goal is to educate children and adults that SUSTA is the first sweetener that helps maintain a healthy lifestyle because SUSTA not only tastes great, but also contains probiotics as well as important vitamins and minerals.

Shaquille O’Neal will support the Company’s national awareness campaign for SUSTANatural Sweetener because it is the only sweetener that is all-natural, low glycemic, contains soluble fiber and probiotics, vitamins C, B6 and B12 and essential minerals and that helps to maintain healthy blood sugar levels, aids digestion as well as supports the immune system.

In 2007, Shaquille hosted a reality TV show on ABC, “Shaq’s Big Challenge,” which featured O’Neal’s effort to help six severely obese middle school aged children from Broward County, Florida to lose weight and gain a healthy lifestyle. The children all started out overweight and were unable to produce adequate results in the President’s Physical Fitness Test and by the end of the challenge they had all lost weight and passed the President’s Physical Fitness Test in all areas.

Eddie George, a Heisman Trophy winner, will promote SUSTA™ Natural Sweetener and Healthy Diary® Yogurt Smoothies in its nationwide expansion.

To raise awareness of the SUSTA brand when SUSTA arrives in Kroger stores in the Columbus, Ohio, area, Eddie George will be making in-store appearances, local television and radio interviews.

George has been an advocate for improving health and wellness among Americans. For the past three years, he and his wife Taj have teamed up with Dr. Oz on “The Dr. Oz Show.” Together they coached and motivated the moms throughout the 2009 NFL season as part of a national viewer challenge to inspire moms and families everywhere to improve their health. The winner of the challenge was announced on the website of the “The Dr. Oz Show.”

In 2006, George was named a spokesperson for Tennessee’s GetFitTN program by Governor Phil Bredesen. GetFitTN is a statewide awareness program to address the rising epidemic of Type 2 diabetes and risk factors that lead to diabetes, such as obesity. This initiative is aimed at educating both adults and children that Type 2 diabetes can be delayed or even prevented with modest lifestyle changes such as increasing physical activity and a healthier diet.

Blair Underwood, an American television and film actor, director, producer and entrepreneur Blair Underwood, will serve as the national spokesperson for NXT Nutritionals and its SUSTA™ Natural Sweetener. For over 20 years, Mr. Underwood has had a successful career playing a wide variety of roles on numerous television and feature films, including his breakout role as a brash attorney on the popular legal drama “L.A. Law” for seven years, his role on the HBO series “In Treatment,” his recurring role on the sit-com “The New Adventures of Old Christine” with Julia Louis-Dreyfus, and his role as Dr. Robert Leeds on the popular HBO series “Sex and the City.” Mr. Underwood has earned two Golden Globe nominations and six NAACP Image awards for offering audiences multi-faceted characters including lawyers, doctors and executives in his film and television work. In addition, Mr. Underwood earned a Grammy Award this year for “Best Spoken Word Album” narrating (with Cynthia Nixon and Beau Bridges) Al Gore’s audio book, “An Inconvenient Truth.” Underwood’s versatility, compelling screen presence, and take-charge appeal proved to be a consistent crowd pleaser with audiences and critics alike. Additionally, Mr. Underwood has produced and directed several short movies and music videos, and is also known for his major contributions through his philanthropic efforts.

Mr. Underwood will represent NXT Nutritionals and their SUSTA™ Natural Sweetener. Blair Underwood is focused on delivering the Company message which addresses the growing epidemic of obesity and diabetes in our country and profiling SUSTA™ Natural Sweetener as a natural healthy alternative to table sugar and the existing artificial sweeteners on the market. Maintaining healthy blood sugar levels, aiding in digestion, and supporting the immune system are critical to a healthy lifestyle. He will educate consumers about the benefits of using SUSTA™ Natural Sweetener.

IN ADDTION NXT Nutritional’s Has a Massive Marketing Campaign

NXT Nutritionals’ has and established broad campaign to increase awareness of the Company’s SUSTA™ Natural Sweetener.

USA Today The paper has the widest circulation of any newspaper in the United States, averaging over 2.11 million copies every weekday.

Go Dairy Free
Review: SUSTA Natural Sweetener (Vegan, Gluten-Free, Nut-Free, Soy-Free)

Broken TeePee
Review: All Natural Sweetener – SUSTA
February 2, 2010

Boston Herald
Company Shoots for Jump in Low-Cal Sweetener’s Sales
January 25, 2010

Healthy Product Reviews
SUSTA Natural Sweetener
January 22, 2010

Non-Dairy Queen
SUSTA Sweetener Review
January 11, 2010

Gluten Free Is Life
Product Review: SUSTA Natural Sweetener
January 8, 2010

The Dirty T-Shirt
Review and Give Away
January 10, 2010

NECN.com Business
BBJ: SUSTA Gains Star Power of Shaq, Underwood
December 30, 2009

Functional Ingredients
New Product: New Fructose-Based Sweetener Stands Up To Stevia
November 11, 2009

Supermarket Guru
Phil Lempert Review
November 4, 2009

Mommys A Waitress
SUSTA Natural Sweetener Review
November 4, 2009

Health & Beauty Close-Up
NXT Nutritional Touts ‘SUSTA’ All-Natural Sweetener
September 16, 2009

That’s Fit
SUSTA is Sweet on Your Tummy and Gut
September 14, 2009

Slashfood
New Sweetener SUSTA Hits Stores
September 10, 2009

Strong Website Presence

Excellent Website Videos Explain Company Dynamics: http://vimeo.com/5591507

The company has dynamic and attractive commercials as well which can be viewed from their website.

NXT Nutritional’s Website offers extensive corporate and retail information providing easy access and credibility to the company.

NXT Nutritionals Holdings, Inc.
President and CEO: Michael McCarthy
800-535-4315
NXT Nutritionals’ corporate website: http://www.nxtnutritionals.com/
Contact: moreinfo@nxtnutritionals.com

Public Relations/Media: Stern & Co.
Richard Stern
212-888-0044
Contact: richstern@sternco.com

Forward-Looking Statements : Under The Private Securities Litigation Reform Act of 1995: The statements in this profilethat relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. No obligation is assumed to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of NXT Nutritionals Holdings, Inc. can be found in the filings of NXT Nutritionals Holdings, Inc. with the U.S. Securities and Exchange Commission.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was paid seven thousand five hundred dollars by a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of NXT Nutritional Holdings, Inc. (OTCBB: NXTH) during the promotional period.

Vicor Technologies, Inc. (OTCBB: VCRT) Text Book Medical Community Recognition

StockGuru — Thu, 11 Mar 2010 14:30:05 +0000

Vicor Technologies, Inc. (OTCBB: VCRT)

Vicor Technologies, Inc. is quickly becoming a biotechnology which is commercially viable. And while I really do not expect you to read each and every Field Trial Entry, Application and Scientific Presentation listed below – I would like you to take a look at the quality and quantity of trials and presentations.

This vast group of Field Trials, Presentations and Publications represents a text book example of a Bio-Technology Company that has delivered a scientifically significant product recognized in the medical community.

These Field Trials, Presentations and Publications lay the ground work for an incredible shareholder opportunity. And this comes on top of the recent association with the leading medical university in Equador with the Universidad San Francisco de Quito in Ecuador. This one collaboration has the potential to vastly enhance shareholder value — and serves as a blueprint for future itnernational commercial awareness.

Current Field Trials and Applications

Vicor has determined the most appropriate rollout of their product is in controlled environments which produce crucial feedback for product enhancement. This means they have the credibility of the Field Trials, Presentations and Publications but they are actively seeking feedback for users in the field. The medical professionals that make the financial purchase decisions. This is smart, smart, smart.

PD2i™ Application in London

PD2i™ nonlinear algorithm has been selected by Dr. Sanjay Sharma to be used in a cardiac screening initiative to be held in London and Southeast England, commencing in April 2010. Dr. Sharma, consultant cardiologist of Cardiac Risk in the Young (CRY), is spearheading the screening initiative which will offer free cardiac screening to 14 year olds (DOB 1995) living in London and Southeast England; fourteen is the earliest post-puberty age for which proactive screening is considered viable. Ten percent of the estimated seven million individuals fitting this description are expected to participate.

The ultimate goal of this initiative is to develop a prototype for a national screening program for young sudden cardiac death, which is an extremely worthy goal, given that some 600 young people are struck down by sudden cardiac death annually in the U.K.

Application Service Provider Distribution Model

A major U.S. cardiology practice serves as the Company’s beta test site for Vicor’s Application Service Provider distribution model which enables the seamless collection and transmission of patient EKG data to the Vicor server for analysis.

Vicor’s software residing on the Company’s servers will complete the analysis of the EKG data read by the PD2i Analyzer™. The physician then receives an electronic medical record and report of the PD2i Analyzer™ results.

The Application Server Provider distribution model records physician use to Vicor’s website to enable automated monthly billing of physicians using its PD2i Analyzer™ and reimbursable under existing CPT codes.

Normal Range Study for the PD2i Analyzer™ Will Serve As Basis For Test Interpretation.

Vicor will be performing a normal range study for the PD2i Analyzer™ at the University of Mississippi Medical Center as soon as routine Institutional Review Board approval is received. This study of approximately 400 age and gender matched “normal” patients will enable us to identify and establish normal ranges of PD2i™ values for these groups, for both a resting patient and a patient performing paced respiration and/or controlled exercise. Vicor will then file a 510(k) with the FDA to establish normal ranges for PD2i™ values. The ability to identify normal ranges will help physicians interpret the results of a PD2i Analyzer™ test as abnormal or normal, which will facilitate accurate diagnosis and appropriate treatment.

Collaborative Studies Continue to Show the PD2i™ Nonlinear Algorithm Enables Accurate Triage of the Seriously Wounded

Testing of the PD2i VS™ by the U.S. Army is continuing under the Company’s collaborative agreement. In the completed study of 325 civilian trauma patients, researchers found that analysis of complex heart rate complexity using the PD2i™ nonlinear algorithm and software identifies trauma patients with good sensitivity (low percentage of false negatives) and that results are similar using both “raw” or “clean” electrocardiograms (“EKG’s”). This latter point is especially important considering the real world – on the battlefield or in civilian trauma settings – in which EKG data is collected. This data for the PD2i VS™ will be used to file a 510(k) to establish a claim for a more accurate triaging of trauma patients.

Additionally, Vicor has completed the programming necessary for the PD2i VS™ to operate as a continuous vital sign monitor. In this mode, the PD2i VS™ provides an initial PD2i™ result within three minutes of collected data and then an updated status every minute thereafter. Each result is accompanied by an audible tone, and a green, yellow, or red light to indicate the patient’s change in status and alert the emergency response team of a need for aggressive and immediate lifesaving intervention. Vicor is completing the modification of the R-R detector in the Company’s software to improve its already high sensitivity and accuracy. (The accuracy of the time intervals between each heart beat “the R-R interval” is critical to the calculation of a PD2i™ value.)

The enhanced version of the continuous PD2i VS™, together with the improved RR detector should enable the USAISR to utilize the Company’s technology in an important prospective human trial.

The PD2i CA™ (Cardiac Analyzer) Expected to Utilize MUSIC Trial Data for New 510(k)

Under a collaborative agreement with the University of Rochester and the Catala Institute of Cardiovascular Science, the PD2i CA™ is being used to study the data files of 651 individuals who participated in the Merte Subita en Insufficiencia Cardiaca (MUSIC) congestive heart failure trial. Vicor has completed analysis of the data files, and expects to have the Company’s collaborators unlock the clinical data and compare the PD2i CA™ results with the actual clinical outcomes in the next six to eight weeks. This time period will permit Vicor to modify the R-R detection software in order to re-analyze the files. This second analysis will enable Vicor to maximize the already high probability of success of this important trial data set. This data set is then expected to serve as the basis for submission of a 510(k) to the FDA for the application of sudden cardiac death (SCD).

Publications, Presentations and Papers

During the past year, the results of the Company’s efforts have appeared in trade media reaching important target audiences, prestigious medical journals, and presentations by USAISR medical personnel.

Trade Media

Dr. Daniel N. Weiss, the Company’s Chief Medical Officer, was interviewed by EP Lab Digest. Medical Device Daily included Dr. Weiss’s comments in an article entitled “Vicor’s heart metric used as an identifier for trauma in patients” (September 25, 2009).

Colonel Leopoldo Cancio of the USAISR identified the PD2i™ as a heart-rate complexity metric to be tested on trauma patients in the Army’s new Critical Combat Care Engineering (C3E) program in “Bridging the Critical Care Chasm,” an article describing the C3E that appeared in the August 2009 issue of Military Medical/CBRN
Technology (Volume 13, Issue 5).

The C3E is a new program area within the U.S. Army Medical Research and Materiel Command’s Combat Casualty Care Research Area Directorate (RAD II) that was created to improve battlefield care and, specifically, address the “critical care technology gap.”

Peer-Reviewed Medical Journals

A manuscript of Vicor’s study, “Comparison of linear-stochastic and nonlinear deterministic algorithms in the analysis of 15-minute clinical EKGs to predict risk of arrhythmic death,” appeared in Therapeutics and Clinical Risk Management (2009-5, 1-12).

The manuscript chronicles the study of 397 patients admitted to three emergency room departments for chest pain and determined to be at low-to-high risk of acute myocardial infarction (MI). Fifteen-minute EKGs were recorded and R-R intervals assessed by three non-linear algorithms (PD2i™, DFA, and ApEn) and four conventional linear-stochastic measures (SDNN, MNN, 1/f-Slope, LF/HF). The sensitivity and relative risk for predicting arrhythmic death was highest at all time-points for the PD2i™ algorithm.

“New Measures of Heart-Rate Complexity: Effect of Chest Trauma and Hemorrhage” is in press in the Journal of Trauma. This USAISR study analyzed the complex beat-to-beat variability present in the heart-rate time series, which has been proposed as a “new vital sign.”

The effect of chest trauma and hemorrhagic shock on heart-rate complexity (HRC) was examined in an animal model. The study concluded that heart rate complexity may be useful for diagnosis of trauma and hemorrhagic shock, and for monitoring resuscitation efforts.

University of Rochester/Catalan Institute of Cardiovascular Sciences

Vicor is working with the University of Rochester and the Catalan Institute of Cardiovascular Sciences to use the PD2i CA™ to retrospectively predict sudden cardiac death in the 651 congestive heart failure patients studied by the Muerte Subita en Insuficiencia Cardiaca (MUSIC) trial, in which 52 actually died from SCD.
Vicor expects that the results of this analysis will be sufficient to support FDA 510(k) clearance for sudden cardiac death in 2010.

University of Mississippi Medical Center

Vicor is collaborating with the University of Mississippi Medical Center on several trials:

Brain Injury Risk Stratification Trial

The BIRST trial will determine the ability of the PD2i™ nonlinear algorithm to predict mortality in victims of brain trauma. PD2i™ will also be assessed for its ability to track the clinical status of neuro-trauma ICU patients.

Brain trauma is a serious public health challenge. In the U.S. over 300,000 sport-related traumatic brain injuries occur annually, and according to the Brain Trauma Foundation, approximately 52,000 will die.

Cardiac Arrhythmia Assessment and Safety in Athletes (CAASA)

Sudden cardiac death is a leading cause of death among student athletes. The CAASA trial will test the ability of the PD2i CA™ to identify those at risk.

The CAASA trial will commence at the University of Mississippi, with follow-on studies at other prestigious universities.

Complexity Analysis Studies of Trauma in the Emergency Department (CASTED)

Vicor is in discussions with the University of Mississippi Medical Center Trauma Center to identify a means of transmitting PD2i-VS™ data during Medivac transport of civilian trauma victims.

Complexity Analysis during Blood Donation (CABLD)

In cooperation with the University of Mississippi Medical Center Blood Bank, the CABLD trial is testing the ability of the PD2i-VS™ to detect mild-to-moderate blood loss as determined during blood donations.

Complexity Analysis during Renal Dialysis (CARD) Trial

CARD will test the use of Heart Rate Variability to evaluate the effect of fluid loss during dialysis.

Massachusetts General Hospital MGH PD2i-VS Trial

In this study, Massachusetts General Hospital will test the PD2i-VS™ for real-time mobile & ICU triage in an extremely demanding emergency medical environment.

The teaching hospital for Harvard Medical School, MGH is a Level 1 Adult, Pediatric and Burn Trauma Center admitting over 4,000 trauma and emergency surgery patients annually.

Dr. Alfred Buxton and Heart Rate Variability

Vicor will be working with renowned electrophysiologist, Dr. Alfred Buxton, on two trials to learn if measuring Heart Rate Variability is useful in tracking the progress of cardiac patients undergoing various rehabilitative treatments following ICD implantation.

Dr. Buxton is a Professor of Medicine at Brown Medical School and Director of the Cardiology Division at Brown Medical School, and Rhode Island and Miriam hospitals. He is also the Director of Arrhythmia Services and the Clinical Cardiac Electrophysiology Laboratory at Rhode Island and Miriam hospitals.

CARE-t Trial

Vicor’s PD2i Analyzer™ will be used to measure Heart Rate Variability as a means of determining the efficacy of cognitive behavioral therapy on cardiac patients with ICDs.

CARE-e Trial

Vicor’s PD2i CA™ is being used to determine the ability of exercise to reduce arrhythmias in cardiac patients with ICDs.

Target Health, Inc.

Target Health, Inc. is working as the Company’s Contract Research Organization in regulatory matters as strategic advisors and clinical consultants for meetings with the FDA.

The Sudden Cardiac Arrest Association

Vicor supports the work of the Sudden Cardiac Arrest Association. The SCAA identifies and unites survivors, those at risk of sudden cardiac arrest, and those interested in advocating for SCAA issues in their communities and beyond. The Sudden Cardiac Arrest Association and Vicor share a mission: to prevent loss of life from Sudden Cardiac Arrest.

PD2i VS™ Presentations and Publications 2009 ATACCC Conference / Smart Monitoring 2009 Forum

Vicor’s technology was presented in August at the 2009 Advanced Technology Applications for Combat Casualty Care (ATACCC) conference and the 2009 Smart Monitoring Forum in St. Petersburg Beach, Florida.

Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), made two presentations. The first, Toward Automated Detection of Life-threatening Injury Using Comprehensive Assessment of the Electrocardiogram, was presented at Smart Monitoring 2009 during the New Vital Signs, Predictive Variables and Indices panel.

At ATACCC, Dr. Batchinsky presented Does Heart Rate Complexity Add to Traditional Vital Signs for Trauma Patient Triage? Both presentations reviewed findings from trials the USAISR has done with Vicor and described use of the PD2i-VS™ as a new vital sign in trauma triage.

The premier scientific meeting of the Department of Defense, ATACCC addresses advances in trauma medicine and the unique medical needs of the war fighter, identifying technologies that can meet increasingly complex operational issues.

Sponsored by the Resuscitation Research Laboratory of the University of Texas Medical Branch, Smart Monitoring is a forum on vital sign monitoring for combat casualty care, facilitating communication between industry representatives and medical experts from government, academia, and the private sector.

2008 International Shock Congress

Exploration of Heart-Rate Complexity to Determine the Need for Lifesaving Intervention in Combat Casualties was also presented by the U.S. Army in June, 2008 at the International Shock Congress in Cologne, Germany. The abstract concerned the initial experiment for trial performed by the U.S.Army on battlefield wounded soldiers utilizing Vicor’s PD2i™ technology.

PD2i ™Technology. Journal of Critical Care

Exploration of Heart-Rate Complexity to Determine the Need for Lifesaving Intervention in Combat Casualties was published in the June, 2008 Journal of Critical Care.

The Company’s first collaborative effort with the U.S. Army, this study involved combat casualties for whom EKG files were analyzed by several competing methods. Vicor’s PD2i™ technology correctly identified the need for immediate life-saving intervention.

Reference: Exploration of heart-rate complexity to determine the need for lifesaving interventions in combat casualties. Journal of Critical Care 2008 Jun;(Vol. 23, Issue 2, Pages 265-266)

Presentations

Andriy Batchinsky, MD, a USAISR researcher, presented findings from a study of Vicor’s PD2i VS™ at the American Heart Association’s Resuscitation Science Symposium 2009 (November 14-15, 2009). Dr. Batchinsky presented “Does Heart-Rate Complexity Analysis Work in the Real World? Changes in the Point Correlation Dimension of Heart Rate during Prehospital Lifesaving Interventions.”

This was the first presentation at a major scientific conference featuring Vicor’s proprietary PD2i™ nonlinear algorithm. The objective of “Does Heart-Rate Complexity Analysis Work in the Real World?” was to evaluate the ability of the PD2i VS™ to distinguish trauma patients receiving lifesaving interventions from those who did not based on analysis of EKGs from 325 pre-hospital trauma patients. The PD2i™ nonlinear algorithm value was calculated on both unedited (raw) and on manually verified, noise-and ectopy-free (clean) EKG sections. In conclusion, researchers found that analysis of heart rate complexity using the PD2i™ nonlinear algorithm and software identifies trauma patients with good sensitivity (low percentage of false negatives) and that results are similar using either “raw” or “clean” EKGs. Additional studies of automated trauma triage using the PD2i VS™ are planned

Additionally, Dr. Batchinsky made the following presentations of the USAISR’s continuing studies of the PD2i VS™:

“Are We Listening to Music or Noise? Use of the Lyapunov Exponent for Comprehensive Assessment of Heart Rate Complexity during Hemorrhage in Sedated Conscious Miniature Swine” 8th International Conference on Complexity in Acute Illness – August 28-30, 2009 – Palo Alto, CA

“Complexity in Animal Models” and “Continuous Complexity Analysis and Remote Battlefield Triage” International Experts of Complexity and Variability at the Bedside Round Table – August 24-25, 2009 – Wakefield, CA

“Does Heart Rate Complexity Add to Traditional Vital Signs for Trauma Patient Triage?” ATACCC 2009 Conference – August 10-12, 2009 – St. Petersburg Beach, FL

“Toward Automated Detection of Life-threatening Injury Using Comprehensive Assessment of the Electrocardiogram” Smart Monitoring 2009 Conference – August 9, 2009 – St. Petersburg Beach, FL

Papers

Therapeutics & Clinical Risk Management

Vicor’s study, Nonlinear Analysis of the Heartbeats in Public Patient EKGs Using An Automated PD2i™ Algorithm for Risk Stratification of Arrhythmic Death was published in the April 2006 Therapeutics and Clinical Risk Management. This study demonstrated the ability of the PD2i CA™ to risk-stratify patients’ risk for sudden cardiac death and identify those who require ICD’s (implantable cardioverter defibrillator) and those who do not.

The study enrolled 37 patients and showed the PD2i test to have a sensitivity of 100% and a specificity of 85%. In other words, Vicor’s PD2i™ nonlinear algorithm correctly identified every patient who went on to suffer a cardiac arrest or sudden cardiac death, while only recommending over-treatment of 15%. Current risk-stratification criteria results in over-treatment of 76% of cases,1,2 while only identifying a fraction of “true-positives” — patients who will go on to experience cardiac arrests or sudden cardiac death.

Risk Stratification for Arrhythmic Death in an Emergency Department Cohort: A New Method of Non-Linear PD2i Analysis of the EKG

The Company’s study of 918 patients in six emergency departments, appeared in the August 2008 issue of Therapeutics and Clinical Risk Management. Vicor’s PD2i® algorithm and software achieved a sensitivity of 96% and a specificity of 85% with a negative predictive value of 99%.

Comparison of Linear–Stochastic and Nonlinear Deterministic Algorithms in the Analysis of 15-Minute Clinical EKGs to Predict Risk of Arrhythmic Death

Published August 17th in Therapeutics & Clinical Risk Management.
The paper describes a study in which 397 emergency room patients presenting with chest pain were evaluated by seven methodologies: the PD2i™ nonlinear algorithm, DFA, ApEn, SDNN, MNN, 1/f-Slope, and LF/HF. The study demonstrated that the PD2i™ nonlinear algorithm, based on a deterministic model, provided superior assessment of Heart Rate Variability in brief EKGs compared to measures based on either the linear stochastic model or other nonlinear ones, and thus provides the basis for a rapid, accurate, and cost-effective stratification of risk of AD among patients presenting in an Emergency Department.

Journal of Critical Care
Exploration of Heart-Rate Complexity to Determine the Need for Lifesaving Intervention in Combat Casualties was published in the June 2008 Journal of Critical Care. The Company’s first collaborative effort with the U.S. Army, this study involved combat casualties for whom EKG files were analyzed by several competing methods. Vicor’s PD2i™ nonlinear algorithm was the only method that correctly identified the need for immediate life-saving intervention in all cases.

American Heart Journal
A Reduction in the Correlation Dimension of Heartbeat Intervals Precedes Imminent Ventricular Fibrillation in Human Subjects appeared in Elsevier’s American Heart Journal. In this study, the PD2i™ nonlinear algorithm and software demonstrated a sensitivity of 100% and a specificity of 83%.

Ongoing Studies
In addition, Vicor is currently involved in several ongoing studies which will be submitted to appropriate publications when complete.

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com

Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.

1 Vicor Technologies, Inc. (OTCBB: VCRT) Goes International — Again

StockGuru — Wed, 10 Mar 2010 20:39:55 +0000

Vicor Technologies, Inc. (OTCBB: VCRT) is in the very advanced stages for a Bio-tech Company. Exactly where a shareholder wants to be.

They have taken their vast published research and credibility international — which means international sales. This time they have the potential to work with the leading Universidad San Francisco de Quito in Ecuador demonstrating the importance of the PD2i™ nonlinear algorithm and software.

Vicor Technologies, Inc. is is focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i™ nonlinear algorithm and software.

Vicor’s recent collaborative agreement with the Universidad San Francisco de Quito in Ecuador has the potential to vastly enhance shareholder value — and serves as a blueprint for future international commercial awareness.

Universidad San Francisco de Quito in Ecuador has two campuses and research facilities, as well as clinics throughout Ecuador, which will enable the outcomes of our collaborative efforts to benefit Ecuadorians throughout the country

The potential exists through this collaboration to further awareness and use of the measure of heart rate variability as a medical diagnostic throughout the entire country of Equador.

Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i(R) nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com

NXT Nutritionals Holdings, Inc. (OTCBB: NXTH) Squarely in the Sweet Spot of Growth

StockGuru — Wed, 10 Mar 2010 14:16:07 +0000

NXT Nutritionals Holdings, Inc., (OTCBB: NXTH) SUSTA™ is keyed in on the newest -hottest - Natural Buzzword of the Future: PROBIOTICS.

NXT Nutrtionals is agressively pursuing the Food & Beverage Additive Industry and PROBIOTICS is a big part of the growth in that industry today.

NXTH is found across the county in retail stores as they establish themselves as a stand along product and have their own line of products.

The sweetener industry represents a $10B a year industry in the United States but NXTH is not content with just the sweetener industry. Well within their grasp is the $8.6B Food & Beverage Additive Industry. Based on all industry outlook NXT Nutritionals finds itself squarely in the sweet spot of growth for BOTH these industries.

NXT Nutritionals will market SUSTA™ in three primary categories:

SUSTA ™ as a table top sweetener alternative to sugar and other sweeteners
SUSTA ™ as an ingredient used in beverages, cereals, baked goods, dairy products, candy and chewing gum
NXT/SUSTA ™ branded products including Healthy Dairy® and other SUSTA™ branded products to be launched by the Company

SUSTA™ is the only sweetening system in the retail marketplace that is all-natural, low glycemic, contains prebiotics (soluble fiber) and probiotics, essential vitamins and minerals, helps to maintain healthy blood sugar levels, aids digestion, and supports the immune system.

NXTH’s future includes playing a key role in the Food & Beverage Additives Industry.

SUSTA™ fits neatly into the Sweetener Industry but it has a key role to play in the Food & Beverage Additives Industry by delivering the newest health additive: PROBIOTICS.

U.S. demand in the Food & Beverage Additives Industry is expected to reach $8.6 billion in 2014.

This represents a huge industry for NXT Nutritionals.

The U.S. food and beverage industry is mature but the sectors anticipated to grow are additives that are able to build market value through the introduction of new and improved products that focus on increasing consumer interest in nutritionally enriched products and all-natural foods. NXT Nutritionals intends to aggresively target this market.

All industry outlooks agree that a high value premium is placed on natural additives. Consumer desire for functional products that provide health benefits will promote demand for additives such as probiotics and other nutraceuticals.

Probiotics and other nutraceuticals are known for their bitter taste. NXT Nutritionals offers a marriage made in heaven. Probiotics with an all natural sweetener.

Nutraceuticals are expected to be fastest growing additives. Nutraceuticals — which include vitamins, minerals, herbal extracts and probiotics — are projected to experience the most rapid gains. Advances will be based on the growing popularity of functional foods containing additives that promote health.

NXT Nutritionals, Inc. has got it all in terms of the right product in growth industries.

On top of that you have a well funded company with product placement in stores RIGHT NOW — to fuel future growth.

NXT Nutritionals represents a classic, text book growth story.

Private Placement Funding

NXT Nutritionals completed a final closing of the private placement offering (the “Offering”) in the amount of approximately $3.3 million. A total of $5.66 million in gross proceeds were raised in connection with the Offering in which the proceeds will be used for general corporate purposes and to fund further development and marketing of its SUSTA™ products.

SUSTA™ and Healthy Dairy®

NXT Nutritionals develops and markets a proprietary, patent-pending, all-natural, healthy sweetener sold under the brand name SUSTA™ and other food and beverage products.

SUSTA™ is being sold as a stand-alone product and it is the common ingredient for all of the Company’s products
Healthy Dairy® is also a developed and marketed product which is enhanced by the revolutionary taste and nutritious ingredients contained in SUSTA™

Susta™ Marketing

NXT Nutritionals will market SUSTA™ in three primary categories:

SUSTA ™ as a table top sweetener alternative to sugar and other sweeteners
SUSTA ™ as an ingredient used in beverages, cereals, baked goods, dairy products, candy and chewing gum
NXT/SUSTA ™ branded products including Healthy Dairy® and other SUSTA™ branded products to be launched by the Company

SUSTA™ is the only sweetening system in the retail marketplace that is all-natural, low glycemic, contains prebiotics (soluble fiber) and probiotics, essential vitamins and minerals, helps to maintain healthy blood sugar levels, aids digestion, and supports the immune system.

SUSTA combats obesity and diabetes while promoting healthier lifestyle with a unique, healthy, delicious products

SUSTA ™ Uses

SUSTA ™ is used in coffees, teas, other beverages, cereals, foods and any other foods that require a sweetener.

SUSTA™ is targeted at individuals craving sweeteners but not the calories from sugar, and is feasible for people with diabetes. Not only does SUSTA™ sweeten the taste of food without all of the side effects of sugars or chemicals, it also contains healthy probiotics, vital dietary fiber, antioxidants and key cellular nutrients, leading to an increased metabolism. SUSTA™ simultaneously supports the health of bones, heart and immune system.

Susta™ Patents: U.S., Canada, Australia, New Zealand

SUSTA™ patents are pending in the U.S. and Canada and patented in Australia and New Zealand.

Retail Market Place Rollout Underway

SUSTA™ is strategically placed in the retail marketplace nationwide
The Healthy Diary® product line is being placed from the east coast to nationwide reach
Healthy Dairy® will be expanded to include product lines such as cup yogurt and ice cream

Albertson’s LLC, Boise, ID, has initiated NXT Nutritional’s expansion into the south for SUSTA™ Natural Sweetener 50 Packet Boxes. Albertson’s operates nearly 230 stores under the Albertsons name in Arizona, Arkansas, Colorado, Florida, Louisiana, New Mexico, and Texas.

With these three additional states SUSTA™ will soon be available in 16 states of the country.

NXT Nutritionals’ products are sold in:

A&P Fresh
Associated Supermarkets
D’Agostino
Food Emporium
Foodtown
Key Food
King Kullen
Kings Super Markets
Kroger
Met Foodmarkets
Pathmark
Pioneer Supermarkets
Shaw’s Supermarkets
ShopRite
Super Fresh
Waldbaum’s

SUSTA™ is being distributed through:

Bozzuto’s Inc., Cheshire, CT
C&S Wholesalers, Keene, NH
Hannaford Bros. Co., Scarborough, ME
United Natural Foods, Inc., Providence, RI
Wakefern Food Corp., Elizabeth, NJ
White Rose, Inc., Carteret, NJ

Recent 2010 Letter to Shareholders

Michael McCarthy, President & CEO, recent Letter to Shareholders for 2010 paints a bright outlook for NXTH.

Dear Shareholders:

It is my pleasure to speak with you today and to discuss all of our various corporate developments to date as well as share our plans for the year ahead. As Chief Executive Officer of NXT Nutritionals, it is my intent to regularly inform our shareholders and the investment community of our progress, as we become uniquely positioned to capture a significant share of the alternative sweetener market with our great tasting and healthier sweetener, SUSTA™ Natural Sweetener.

As you already know, SUSTA is a cutting-edge, natural sweetening system that is poised to revolutionize the alternative sweetener marketplace. It has minimal calories, no lingering aftertaste and is all-natural. Not only does SUSTA sweeten the taste of food without all of the side effects of sugars or chemicals, it also contains healthy probiotics; vital dietary fiber; antioxidants and key cellular nutrients – leading to an increased metabolism. SUSTA simultaneously supports the health of your bones, heart, and immune system. This is in contrast to many of the other leading sweeteners in the marketplace, which either use chemicals to achieve their sweetening effects or are natural sweeteners with no added health benefits.

SUSTA is currently being sold as a stand-alone sweetener in a 50-packet box and is in our Healthy Dairy® Yogurt Smoothies. In addition, we recently announced the launch of our baking version of the sweetener, which is currently available for pre-order on our e-commerce site, http://www.sustastore.com/.

The 50-packet boxes of SUSTA are now available in approximately 1,200 supermarkets in the Northeast region including, ShopRite, Shaw’s Supermarkets, Pathmark, A&P Fresh, Super Fresh, Waldbaum’s, Food Emporium, Associated Supermarkets, Foodtown, Kings Super Markets, Pioneer Supermarkets, Met Foodmarkets and Key Food.

We have also announced that the product has been authorized in The Kroger Co., one of the nation’s largest grocery retailers with 2008 sales of $76.0 billion. This establishes a footprint into the Midwestern region.

I am privileged to have two great role-models and advocates to healthy living, actor Blair Underwood and National Basketball Association star Shaquille O’Neal, as spokespersons for our product. Brand awareness of SUSTA is a crucial component to better promoting all of our products. With the added health benefits of SUSTA, especially for diabetics and people with weight management issues, we intend to partner with a number of health organizations to also endorse SUSTA.

We believe that 2010 will be an extremely exciting year for us. We have already seen a great response to our SUSTA™ Natural Sweetener, and we expect to see continued brand recognition by consumers, retailers, the health community and the medical community. SUSTA’s potential increase in popularity will be driven by the simple fact that consumers are looking to reduce the amount of sugar they use and are looking to eliminate artificial products from their diet. We believe that SUSTA is the healthiest alternative to sugar currently available.

I expect the Company to meet several milestones this year as we move into a growth phase.

We will continue to add retail distribution for our product so that we may have a national presence in grocery chains across the country. Our goal is to be in over 5,000 locations this year and to expand the SUSTA product line by adding additional “SKU’s”.

The Company will continue to grow both the SUSTA and Healthy Dairy product lines in additional distribution channels other than grocery chains that will include contact feeders, big box stores, drug stores, health and nutrition stores and fast food restaurants. As we continue to build brand and product awareness, SUSTA can easily be incorporated into the table top sweetener caddies in restaurants.

As more and more food and drink products are being produced to meet the demand of the more health conscious consumers, we will be looking to partner with other food companies to have SUSTA™ Natural Sweetener as the sweetener of choice in their products. These companies will be able to offer their consumers a product with a much healthier sweetener than is currently being used.

In addition, we will look to expand upon our Medical Advisory Board to help the Company address the health problems surrounding, obesity, poor nutrition and diabetes. I intend to capitalize on the Boards expertise and guidance in addressing these growing issues as we look to provide the consumer scientific insight, health and wellness information on the benefits of using SUSTA.

In conclusion, over the last several years, we were in the developmental stage, planning and preparing to launch our products. Today, we have built the infrastructure and positioned a great team of experts to take us to the next level. I believe this year is “our year” and that we will become a recognized force in the industry.

I thank you for your attention and support. For further additional updated information, please visit our website at www.nxtnutritionals.com.

I look forward to communicating with you again soon.

Sincerely,

Michael McCarthy
President and CEO – NXT Nutritionals Holdings, Inc.

Brand Awareness Campaign Enlists National Celebrities

Shaquille O’Neal, National Basketball Association star, Eddie George and Blair Underwood Public Face of Susta™ and NXT Nutritional Holdings, Inc.

Eddie George, a Heisman Trophy winner, will promote SUSTA™ Natural Sweetener and Healthy Diary® Yogurt Smoothies in its nationwide expansion.

To raise awareness of the SUSTA brand when SUSTA arrives in Kroger stores in the Columbus, Ohio, area, Eddie George will be making in-store appearances, local television and radio interviews.

NXT Nutritional’s Massive Marketing Campaign

NXT Nutritionals’ has and established broad campaign to increase awareness of the Company’s SUSTA™ Natural Sweetener.

USA Today The paper has the widest circulation of any newspaper in the United States, averaging over 2.11 million copies every weekday.

Go Dairy Free
Review: SUSTA Natural Sweetener (Vegan, Gluten-Free, Nut-Free, Soy-Free)

Broken TeePee
Review: All Natural Sweetener – SUSTA
February 2, 2010

Boston Herald
Company Shoots for Jump in Low-Cal Sweetener’s Sales
January 25, 2010

Healthy Product Reviews
SUSTA Natural Sweetener
January 22, 2010

Non-Dairy Queen
SUSTA Sweetener Review
January 11, 2010

Gluten Free Is Life
Product Review: SUSTA Natural Sweetener
January 8, 2010

The Dirty T-Shirt
Review and Give Away
January 10, 2010

NECN.com Business
BBJ: SUSTA Gains Star Power of Shaq, Underwood
December 30, 2009

Functional Ingredients
New Product: New Fructose-Based Sweetener Stands Up To Stevia
November 11, 2009

Supermarket Guru
Phil Lempert Review
November 4, 2009

Mommys A Waitress
SUSTA Natural Sweetener Review
November 4, 2009

Health & Beauty Close-Up
NXT Nutritional Touts ‘SUSTA’ All-Natural Sweetener
September 16, 2009

That’s Fit
SUSTA is Sweet on Your Tummy and Gut
September 14, 2009

Slashfood
New Sweetener SUSTA Hits Stores
September 10, 2009

Strong Website Presence

Excellent Website Videos Explain Company Dynamics: http://vimeo.com/5591507

The company has dynamic and attractive commercials as well which can be viewed from their website.

NXT Nutritional’s Website offers extensive corporate and retail information providing easy access and credibility to the company.

Board of Directors and Management
Michael McCarthy, President & CEO / Director

NXT Nutritionals, Inc. is led by entrepreneur and food and beverage industry veteran Mike McCarthy, an executive with over 25 years of experience in the sector. He is the former Vice President of Pepsi-Cola’s Fountain Solutions. While at Pepsi, he was responsible for the development and integration of their Citrus Hill juice products. Michael was also instrumental in the negotiation and subsequent integration of Hawaiian Punch into the Pepsi-Cola system. The results of this assimilation increased fountain sales more than five hundred percent. Mr. McCarthy was also a key component in a national sales effort that was successful in landing several large national accounts. Additionally, he was part of a special acquisition team that was working to increase Pepsi-Cola’s fountain presence.

As an entrepreneur Michael has been the driving force behind the development of numerous beverage products. He was responsible for the development of Juice Creations, a product that was successfully launched in Massachusetts and then expanded nationally. After selling his business, Juice Creations, to Pepsi Cola, Mr. McCarthy built the Juice Creations product line into a $63 million business in the first year after Pepsi Cola’s acquisition.

After his career at Pepsi-Cola, he was instrumental in the growth of Al’s beverage Company from a small independent manufacturer to one of the largest independent Royal Crown Cola fountain manufacturers in the United States. In his position as COO of Al’s Beverage Company Michael was responsible for building and operation of one of the most modern independent fountain plants in the country.

Richard M. Jordan, Executive Vice President, General Manager / Director

Richard Jordan is an expert in branding and sales promotions, with over twenty five years experience in sales, marketing and retail. He received a Bachelor of Science Degree in Advertising and Marketing from Arizona State University, and holds a Masters Degree from Cornell University in Business and Marketing.

After graduating from college, Richard began his career in the food industry with Nabisco Foods, Inc. After three years with Nabisco, Richard was promoted through various positions, achieving the position of Sales Manager, was honored as Salesman of the Year for Nabisco Brands and served as assistant to the Vice President of Sales and Marketing.

In 1983 Richard joined The New York State Food Merchants Association, a lobbying and trade relations firm, accepting the position of Director of Trade Relations. In 1987 he was promoted to the office of Executive Vice President and General Manager, the position held until his resignation in 1991.

Richard then served as President at Jordan Associates Inc., a food brokerage firm, specializing in introducing new products from both small and fortune 500 companies. Prior to his current position at NXT, Mr. Jordan was Vice President of Sales for Healthy Dairy, LLC, now a wholly owned subsidiary of NXT Nutritionals, Inc. In addition to being past President of The Catholic Institute of the Food Industry, Richard chairs a committee on the Food Industry for Covenant House. He sits on the board of directors for the Deborah Heart and Lung Foundation in New Jersey. He also is on the advisory committee for Calvary Hospital in New York City.

Mark A. Giresi, Director and COO

Mark A. Giresi is a retail executive with almost 25 years of experience in various operations and legal roles in the United States and internationally. Most recently, he served as Executive Vice President, International for Limited Brands, Inc., a $9 billion dollar specialty retail business trading under the Victoria’s Secret, Bath & Body Works, White Barn Candle Co., and Henri Bendel brands. In that role, he led the development of the Company’s International growth strategy and the day-to-day management of the growth of Victoria’s Secret and Bath & Body Works outside of the United States. In May 2005, he was appointed EVP, Retail Operations, responsible for the Company’s Real Estate, Store Design and Construction, Visual Merchandising, Store Operations, and Loss Prevention and Brand Protection functions. He was on the Executive Committee of the Company, responsible for its strategy and the overall business performance of its branded specialty retail businesses.

Mr. Giresi joined Limited Brands in February, 2000 as Vice President of Store Operations and in August, 2001 was promoted to Senior Vice President, Chief Stores Officer for the Company’s almost 4,000 retail stores.

Prior to joining Limited Brands, Mr. Giresi was Senior Vice President of U.S. Franchise Operations and Development for Burger King Corporation, responsible for the restaurant operations and support to almost 8,000 franchise-owned and operated stores together with all real estate investments in the U.S. business. From 1993 through 1998 he held the position of Senior Vice President, Worldwide General Counsel and Secretary for Burger King. During that time, he was also a member of the Board of Directors of Restaurant Services, Inc., the independent purchasing cooperative for the U.S. Burger King System. He began his career with Burger King as a real estate attorney in 1985 and has published numerous articles and spoken on various franchise and intellectual property law topics. Mr. Giresi was a member of the first United States – South Africa Commercial Law Delegation established by the United States Department of Commerce and the government of South Africa.

Mr. Giresi has served on several philanthropic and business association boards, including the Board of Directors of the Beacon Council, the business development agency for Miami-Dade County, Florida, the Miami Philharmonic and the International Franchise Association. He currently serves on the Board of Directors of UFood Grille, a publicly-traded, franchised restaurant business, Fiduciary Trust International of the South, an investment management firm, and the Boys and Girls Clubs of Columbus, Ohio, where he served as the Treasurer and a member of the Executive and Human Resource committees.

Mr. Giresi is a past recipient of the Italian-American businessman of the year by the National Italian American Foundation in South Florida. In 2004, he received the Champions Award from Safe Horizons, a leading domestic violence prevention organization in New York City. He is an attorney at law of the State of New Jersey. He earned a law degree in 1983 from Seton Hall University and a Bachelor of Science degree in accounting in 1980 from Villanova University.

Ann E. McBrien, Director

McBrien is a veteran sales and marketing executive with more than 25 years of business experience, ranging from starting her own businesses to a leading national and international organization. She was the first female Vice President of Sales in Procter & Gamble (P&G) history in 1999.

From 1982 to 2001, McBrien’s held a variety of executive positions with increasing responsibility at P&G. During her tenure at the consumer foods giant, she was known for building strong relationships with major international retail clients, increasing global health care sales and developing a merchandising program, global pricing and promotion plans for global customers.
From 2002-2006, McBrien co-founded OT OverTime, LLC, a company with a line of hair and body care products for boys with the brand name “OT.” The company acquired the brand from P&G. OT OverTime introduced the line nationally to major retail chains, including the supermarket chain, The Kroger Co., and Target Corp., a national retailer.

Currently, McBrien is a consultant to Tremor, a division of P&G. Tremor, which provides clients with a word-of-mouth marketing program, has relationships with 400,000 moms to share brands and brand benefits of products marketed by other companies as well as P&G to their friends.
Ms. McBrien has a B.S. in Finance from the University of Illinois. She is active in educational and community organizations.

Paul S. Auerbach, MD, MS, Director

Dr. Paul S. Auerbach is a Professor of Surgery in the Division of Emergency Medicine at Stanford University Medical. He will be forming and heading the Company’s Medical Advisory Board. He is the former Professor and Chief of the Divisions of Emergency Medicine at Stanford and Vanderbilt. Dr. Auerbach is a founder and past president of the Wilderness Medical Society, editor of the definitive medical reference text Wilderness Medicine, 5th Edition, and author of Medicine for the Outdoors, which is a leading book on outdoor health for laypersons.

Dr. Auerbach practices emergency medicine, teaches, performs research, and advises numerous agencies and organizations, including serving as an advisory board member to the AARP “Fat 2 Fit” Community Challenge. Dr. Auerbach has been hailed as a Hero of Emergency Medicine by the American College of Emergency Physicians. He also serves on the National Medical Committee for the National Ski Patrol. Dr. Auerbach is a recipient of numerous awards including the DAN America Award from the Divers Alert Network, Outstanding Contribution in Education Award from the American College of Emergency Physicians, a NOGI Award in 2006 from the Academy of Underwater Arts and Sciences, Diver of the Year for Science in 2008 from Beneath the Sea, and DAN/Rolex Diver of the Year in 2009.

Dr. Auerbach is a graduate of Duke University and Duke University School of Medicine, as well as the Stanford Graduate School of Business.

Ted Mandes, Director

Ted Mandes is an experienced entrepreneur, executive and investor, however his philanthropic and charitable work is what he is most proud of.

Mr. Mandes played professional golf until 1975, and then entered the business world as an account executive in the ladies apparel business. After a successful stint in New York, he founded Mandes and Associates. It was during this time that Mr. Mandes honed his marketing skills to make his company one of the largest agents to the trade. During his career in the apparel business, Mr. Mandes developed divisions of Federated Department Stores, May co. JC Penny and other multiple store groups into multi-million dollar accounts for many of the major wholesale companies that his firm represented.

As an investor, Director and entrepreneur, Mr. Mandes has consistently recognized and understood trends well ahead of the rest of the market, from new innovations in apparel to developing inserts and needs for diabetic patients with conditions like peripheral neuropathy.

In 1994 he founded Bioform, Inc. with Stephen Warner, a pedorthic foot care company that dealt with orthopedic foot problems but also addressed the needs of diabetics. While developing this opportunity, the urgent need to address the alarming increase in the incidence of obesity and diabetes in the United States became apparent to Mr. Mandes.

Mr. Mandes sits on the Board of Directors of the Raymond F. Kravis Center and the Palm Beach Counties performing arts center. He also developed and chairs the Palm Beach Wine Auction, the most productive fundraising event for the performing arts center’s award winning education department. Ted’s mission “is to further advance the educational experience of our youth – it is more than just a cause it is an ongoing obligation.” Over 85,000 students have attended live performances camps and other workshops every year for the past 16 years.

David Deno, Director

David Deno is a veteran executive with over 27 years of experience in the restaurant industry having held various key positions including President, CEO and CFO of public and private companies.

Prior to joining NXT’s Board of Directors, Mr. Deno served as President and CEO for Quiznos LLC. Beginning in August 2006, he was a Managing Director with the private equity firm CCMP Capital Advisors, LLC an ownership partner in Quiznos which led David to his executive positions at Quiznos.

Prior to August 2006, he spent more than 15 years with YUM! Brands, Inc. (NYSE: YUM – News) and PepsiCo (NYSE: PEP – News). At YUM! Brands Mr. Deno served as Chief Operating Officer from October 2004 to February 2006 and as Chief Financial Officer from November 1999 to October 2004. He was instrumental in growing YUM! Brands and building shareholder value after its spin-off from PepsiCo in 1997. Mr. Deno also held senior positions in YUM!’s International and Pizza Hut divisions. Prior to joining YUM! David worked for Burger King Corporation (NYSE: BK – News) and The Pillsbury Company in various finance, real estate, and operations assignments.

Dr. Richard L Kozlenko – Consulting Director of R&D and Quality Control
D.P.M., M.P.H., Ph.D.

Professional Background and Experience

INNOVATIVE NUTRACEUTICALS 2006: JV in creating patent-pending, proprietary and unique brewery solids invention, regarding the synergistic, antioxidant properties with Vitamins E and C in a lipid management system.
FUELCeL (TM) 2006: Private, self-funded venture involving new innovation in energy bar formulation and technology. Company start-up including proprietary coating formulation. Trademark 2006.
SUSTA™ 2004: Principal author and developer of primary features of this IP. Co-developing website and expanded market applications in beverage and dry good applications. SUSTA™ technology centers on the control of the adverse effects of sugar on blood sugar and insulin response in functional foods and beverages. Original human studies conducted at the University of Scranton proved efficacy of product.
HEALTHY DAIRY 2002: Formulated and positioned nutraceutical yogurt drink beverage marketed in major private label venues such as Wal-Mart (1300 stores). Product was reformulated as “all natural” with additional features, with major distributors and brokers throughout East coast and in Whole Foods nationally.
NXT NUTRITIONALS, LLC 1999: Formulated functional beverages, carbonated and flat drink lines, for beverage R and D Start-up Company. Author of three White Paper technical reports concerning the health positioning/ingredient strategies of beverages.
MEDOCTOR INC. 2001: Point person on an international medical development and quality control team for multiple patented inventions in telemedicine, designed to provide primary and secondary medical diagnosis from client data entry. Product targeted for B to B and B to C applications.
HEALTHSHOP.COM, 1999-2000: Designed and authored major wellness programs including the essential logic and algorithms. Worked closely with engineering, marketing, editorial and design to overview project. Designed proprietary nutritional products, serve on the Scientific Quality Assurance Board and Board of Scientific Advisors.
CLINICAL NUTRITION, 1997-2001: Multidisciplinary team practice with patients on specialized diets ranging from food sensitivities and allergies, weight-management issues, cardiovascular, diabetic, etc. Worked part-time with clients integrating nutritional approaches with specialized fitness training.
EARTHRISE TRADING COMPANY, 1996-1998: Formulator of finished products including supplements and functional foods, research in the pharmacognosy and nutraceutical applications/ evaluation of new ingredients, spirulina derivatives, and formulated products; co-chairman of the Scientific Advisory Board for Earthrise Trading Company and Earthrise Farms, associate in marketing and sales support. Developed product and point of sale materials for Earthnet, Earthrise’s network marketing division.
I.C. REFRESHMENT CO, 1993-1998: Scientific and Nutrition Director: Developed and created new functional beverage formulation for a major mass-market beverage company, scientific foundation for product nutritional positioning, point of sales materials, scientific research.
PARALLEL PRODUCTS, 1995-1998: Spearheading nutraceutical, and pharmacognosy research and applications of brewery solids in conjunction with the Functional Food Department of the University of Chicago, University of Scranton. Original research finding positive synergy between vitamin E and brewery extract in animal heart model studies.
GLOBAL VISION INC, 1994-1996: Infomercial and networking marketing Company. Developed and formulated products, point of sales materials, marketing team resource.
FREEDOM WEIGHT-LOSS CLINICS, 1993-1996: Consultant. Developed and authored lay and professional information, clinical nutritional syllabus for physicians for weight management, proprietary formulations
INTER-CAL CORP., 1993-1994: Consultant. Spearheaded new applications of Ester-C in conjunction with marketing and research roles. Worked closely with UCSF School of Preventive Dentistry in original research and electron microscopy evaluating erosive nature of conventional vs. Ester C on dental enamel and inhibition of plaque bacteria with various vitamin C salts.
COLUMBIA PACIFIC UNIVERSITY, 1988-1994: Director of Health Enrichment. Implementation, author and development of computerized wellness curriculum for international students approved by the State of California for higher education. Faculty mentor since 1978 for students matriculating at Master’s and Doctoral levels in health, clinical and nutritional sciences.
MILL VALLEY PODIATRY AND SPORTS MEDICINE GROUP, 1984-1990: Physician and Surgeon in a group practice that emphasized sports medicine, rehabilitation, fitness, and orthopedics.
WHOLISTIC HEALTH AND NUTRITION INSTITUTE (WHN), 1973-1984: Director and Co-Founder of nationally acclaimed non-profit institution for holistic and traditional medicine, education for public and health professionals. Clinical nutrition, clinical ecology, non-invasive therapies, sports medicine, community education. Elective Family Practice residency rotations through WHN with Stanford Medical School and San Francisco Public Health Hospital. CEU credits approved for nurses and physicians.
METABOLIC NUTRITION: 2003 Training and consulting in principles and practice of metabolic nutrition that uses specialized diets predicated on specific laboratory findings of how an individual oxidizes nutrients.
RECOVERY SYSTEMS: 2002 Six-week preceptership in nutritional intervention and metabolic assessment protocols related psycho biochemical conditions focused on behavior, mood, and addictions.
UCSF SCHOOL OF MEDICINE GRANDROUND SEMINARS: Invitational postgraduate clinical seminars Department of Endocrinology and Metabolism (1 yr)
UCLA SCHOOL OF MEDICINE AND PUBLIC HEALTH, Master’s in Nutritional Biochemistry and Public Health (MPH)
CALIFORNIA COLLEGE OF PODIATRIC MEDICINE, Doctor of Podiatric Medicine (DPM)
COLUMBIA PACIFIC UNIVERSITY, Doctor of Philosophy, Wellness Education (Ph.D.)
UCLA, Bachelor of Science in Zoology and Biology (B.S.)

Professional and Honor Societies (elected to membership):

Fellow, International Food Technologists
Fellow, New York Academy of Sciences (Nutrition)
American Podiatry and Sports Medicine Association
American Academy of Sports Medicine
Royal Society of Health
American College of Nutrition
California Orthomolecular Society
American College of Public Health and Nutrition

Special Projects

On survey development team for Cancer Research Fund for epidemiological studies trying to better understand potential risk factors unique to Marin residents.

Publications and Authorship

Primary author of two nutraceutical patent-pending inventions in association with the University of Scranton Dept. of Food Chemistry, Joe Vinson Ph.D. 2001, 2002.
Nutritional Editor, Healing 2000, Health and Happiness Publishing, 1999
Associate Editor and Writer, Health World Magazine, 1993-1996
Stepping Stones To Nutritional Awareness, CPU Press, 1978
Lifestyle and Environment, computerized wellness curriculum for Columbia Pacific University, 1987
Color Code System, behavioral modification program for changing eating habits and food selection patterns (unpublished)

Media Presentations and Lectures

Psychology Today, “Eating Habits of Americans,” co-authored with Sam Keen, Oct. 1979
Prevention Magazine, major interviews in three issues, 1979.
KGO radio, ABC-TV, NBC-TV, Canadian Radio, Infomercials, Evening Magazine, etc.

Lectures: San Francisco State, UCLA, UC Medical and Dental Schools, San Jose State, Mt. Zion Hospital, numerous community organizations. Numerous articles and on camera segments over the years in nutrition and health.

Dr. James R. Gavin III, Medical Advisory Board Member

Dr. Gavin currently serves as Clinical Professor of Medicine at Emory University School of Medicine in Atlanta, Georgia, as Clinical Professor of Medicine at the Indiana University School of Medicine, Indianapolis, Indiana and Chief Executive Officer and Chief Medical Officer of Healing Our Village, Inc.

Dr Gavin belongs to numerous relevant organizations, including the Institute of Medicine of the National Academy of Sciences, the American Diabetes Association (ADA), the American Society of Clinical Investigation and the American Association of Clinical Endocrinologists (AACE). He is a past President of the American Diabetes Association and was voted Clinician of the Year in Diabetes by the ADA in 1991.

Active in clinical research, Dr. Gavin has authored and co-authored more than 200 articles and abstracts for such publications as Science, Journal of Applied Physiology, Diabetes, and the American Journal of Physiology. He is the recipient of numerous awards, including the Daniel Hale Williams Award, the Banting Medal for Distinguished Service from the American Diabetes Association and Internist of the Year Award from the National Medical Association. He is also a recipient of the 2009 Living Legend in Diabetes Award from the American Association of Diabetes Educators. Dr. Gavin graduated with a degree in chemistry from Livingstone College, a doctorate in biochemistry from Emory University and a medical degree from Duke University.

NXT Nutritionals Holdings, Inc.
President and CEO: Michael McCarthy
800-535-4315
NXT Nutritionals’ corporate website: http://www.nxtnutritionals.com/
Contact: moreinfo@nxtnutritionals.com

Public Relations/Media: Stern & Co.
Richard Stern
212-888-0044
Contact: richstern@sternco.com

Medizone International, Inc. (OTCBB: MZEI) Building Four Instrumented Prototype units

StockGuru — Wed, 10 Mar 2010 14:00:08 +0000

Four Instrumented Prototypes

Medizone International announced unprecedented success in being able to predictably achieve 6 log (99.9999%) kill rates for the causative agents of Hospital Acquired Infections (HAIs) represented with AsepticSure™.

Medizone will build four highly instrumented prototype units for use in its hospital program.

The four intrumented prototypes will allow for a precise performance assessment of all AsepticSure™ systems.

This will form the basis for final production design work, manufacturing and ultimately commercialization later this year.

By introducing the same combinations and protocols to room scale testing results coincided with what had been achieved in the most recent round of laboratory trials.

All samples were either completely destroyed, that is no growth compared to the control samples, or so significantly reduced that the effect met the 6 log definition for sterilization.

The actual results of this series of tests indicate reductions in pathogens, commonly associated with HAIs, can reliably be achieved by AsepticSure™ as follows:

In parallel research conducted at BioZone Corporation, Medizone’s engineering development partner, it was confirmed the AsepticSure™ hospital sterilization system can charge a room of 1,065 cubic feet to the target ozone level in less than 15 minutes, which is followed by the ozone decontamination phase. The same room can then be returned to a habitable standard (less than 0.02 ppm ozone) in 13 minutes using a separate ozone destruct technology. This confirms the start to finish time to complete the entire decontamination process can be achieved with minimal disturbance to normal hospital flow patterns.

Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Medizone International, Inc. (OTCBB: MZEI) Potential to Eliminate 99.999992% Anthrax in 90 Minutes

StockGuru — Wed, 10 Mar 2010 00:06:45 +0000

Medizone International, Inc. (OTCBB: MZEI) has a secondary focus in addition to Hospital Acquired Infections; Bioterrorism Applications. This provides an second revenue source for the company delivering enhanced shareholder value.

A field hardened version of AsepticSure™ is anticipated to be used in Bioterrorism internationally. It will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and has the potential to save lives. The potential of being able to eliminate 99.999992% (7.2 log kill) of an internationally accepted surrogate for Anthrax in 90 minutes will have national security implications.

Why Medizone?

Medizone has a 23 year history in the field of medical therapeutics with Ozone.
Medizone has initiated a joint program with Biozone Corporation to develop a state-of-the-art Ozone-based sterilization system (AsepticSure™) for medical applications.
This technology will feature a new “Ozone Destruct” scrubbing system intended to rapidly detoxify hospital working spaces following exposure to Ozone.
The Medizone technology (AsepticSure™) will have an Ozone producing capacity significantly greater than what is thought to be necessary under normal hospital circumstances.
The AsepticSure™ system will also include a gas vaporization component, and a stand alone Ozone scrubbing system, adaptable to all hospital environments and space requirements.
The AsepticSure™ will be marketed for bioterrorism applications

Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Medizone International, Inc. (OTCBB:MZEI) Amazing Entry Point This Morning

StockGuru — Tue, 09 Mar 2010 14:01:35 +0000

Medizone International, Inc.(OTCBB: MZEI)

VIEW PROFILE – VIEW MEDIZONE WEB SITE

Dear Members:

Today represents a great opportunity for MZEI. Yesterday’s news continues to confirm the amazing opportunities. I have the utmost confidence in this company and believe the ELIMINATION OF SUPER BUGS in a world where Hospital Acquired Infections kill THREE TIMES AS MANY PEOPLE AS AIDs is a gigantic step forward.

Strange how share price does not immediately follow GREAT NEWS LIKE THIS: AsepticSure(TM) Eliminates All Pathogens

Medizone has come a long, long way since it was first introduced by Stock Guru on June 2, 2009, at $00.042. (four cents).

MZEI has been completely successful in the completion of the first full round of room scale testing with AsepticSure™.

With the design of the first pre-manufacturing prototype about to begin we can see the commercialization of AsepticSure™ in the very near future.

If there were a solution on the market now 100,000 people a year would NOT be dying from Hospital Acquired Infections. Medizone International has a very important solution.

Contact information:
Medizone International, Inc. (OTC: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 532,200 144 restricted common shares by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We currently hold 332,200 shares.

NXT Nutritionals Holdings, Inc. (OTCBB: NXTH) Sweetener Industry $10B a Year

StockGuru — Tue, 09 Mar 2010 12:04:33 +0000

NXT Nutritionals Holdings, Inc. (OTCBB: NXTH)

SUSTA™ was developed and is marketed by NXT Nutritionals Holdings, Inc. This sweetner is a healthy alternative for food and beverage products and most importantly IT LEAVES NO BITTER AFTERTASTE.

Healthy is the future for all food products and the artificial sweetner sector has room for big growth. In the United States the artificial sweetner business is a $10B a year business and is currently dominated by Splenda and aspartame. Splenda recently delivering more than $225 million in sales.

This is good news for SUSTA™.

SUSTA™ Natural Sweetener, can meet Splenda head on in terms of taste and calories. It is a minimal calorie, all-natural, nutritional sweetening system sold as a standalone product as well an ingredient for food and beverages.

The BIG DEAL about the SUSTA™ Natural Sweetener is that it does NOT leave a bitter after taste.

Why is this a BIG DEAL?

Because NO BITTER AFTERTASTE is what puts NXTH on the map — this is why SUSTA™ has a strong claim to the future in the sweetener industry — whether being used as a standalone product or as an ingredient in foods or beverages.

Artificial sweeteners have been around since the 1960s. The common sweeteners we all know, have caused increasing and growing concern because of their chemical components. New mothers are determined to provide their children with healthy and natural alternatives and go out of their way to find them. Teens understand the importance of natural. Adults are weight and health conscious. Everyone understands there are risks associated with chemical product and if there is a healthy natural alternative — that alternative is becoming the product of choice.

In the Natural Sweetner Industry SUSTA™ has one main competitor, Stevia. The good news is that Stevia which was approved by the U. S. Food and Drug Administration as recently as 2008, leaves a bitter aftertaste. You don’t have to take my word for the bitter aftertaste — or NXTH’s word about the bitter aftertaste left by Stevia. Major news organizations have noted its bitter aftertaste. Bitter aftertaste is just a plain fact for SUSTA™’s main rival.

Healthy competition for a healthy product means in terms of taste and aftertaste SUSTA™ wins, hand down and there is lots of room in at $10B a year industry.

NXT Nutritionals Holdings, Inc.
President and CEO: Michael McCarthy
800-535-4315
NXT Nutritionals’ corporate website: http://www.nxtnutritionals.com/
Contact: moreinfo@nxtnutritionals.com

Public Relations/Media: Stern & Co.
Richard Stern
212-888-0044
Contact: richstern@sternco.com

Medizone International, Inc. (OTCBB: MZEI) Total Elimination of Super Bugs

StockGuru — Tue, 09 Mar 2010 00:00:09 +0000

Medizone International, Inc.(OTCBB: MZEI)

VIEW PROFILE – VIEW MEDIZONE WEB SITE

Dear Members:

The value here is the stock has been TWICE the current price in recent months, and yet it has never been closer to TOTAL SUCCESS…

Strange how share price does not immediately follow GREAT NEWS LIKE THIS: AsepticSure(TM) Eliminates All Pathogens

Medizone has come a long, long way since it was first introduced by Stock Guru on June 2, 2009, at $00.042. (four cents).

The mock trials are now at their final stages and reporting the total elimination of Super Bugs in the hospital mock up room — this represents and incredible accomplishment.

Today’s news undersores the incredible success MZEI has had in the successful completion of the first full round of room scale testing with AsepticSure™.

The sterilization system indicated all pathogens Hospital Acquired Infections were completely eliminated at concentrations well above 6 log.

The design of the first pre-manufacturing prototype to be used in hospital beta testing is about to begin.

The AsepticSure™ Hospital Sterilization System has demonstrated the total eradication of Super Bugs. Every full scale test run completed in the hospital room mock up facility has resulted in the total elimination of all bacteria present in the room.

Contact information:
Medizone International, Inc. (OTC: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 532,200 144 restricted common shares by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We currently hold 332,200 shares.

StockGuru.com » StockGuru

Medizone International, Inc. (OTCBB: MZEI) New Message from Chairman Addresses Recent Issues

Chairman’s Message Shareholder Update

March 11, 2010

NXT Nutritionals Holdings, Inc. (OTCBB: NXTH) Susta™ Savvy Media and Marketing

Vicor Technologies, Inc. (OTCBB: VCRT) Text Book Medical Community Recognition

1 Vicor Technologies, Inc. (OTCBB: VCRT) Goes International — Again

NXT Nutritionals Holdings, Inc. (OTCBB: NXTH) Squarely in the Sweet Spot of Growth

Medizone International, Inc. (OTCBB: MZEI) Building Four Instrumented Prototype units

Medizone International, Inc. (OTCBB: MZEI) Potential to Eliminate 99.999992% Anthrax in 90 Minutes

Medizone International, Inc. (OTCBB:MZEI) Amazing Entry Point This Morning

VIEW PROFILE – VIEW MEDIZONE WEB SITE

NXT Nutritionals Holdings, Inc. (OTCBB: NXTH) Sweetener Industry $10B a Year

Medizone International, Inc. (OTCBB: MZEI) Total Elimination of Super Bugs

VIEW PROFILE – VIEW MEDIZONE WEB SITE

The value here is the stock has been TWICE the current price in recent months, and yet it has never been closer to TOTAL SUCCESS…

Strange how share price does not immediately follow GREAT NEWS LIKE THIS: AsepticSure(TM) Eliminates All Pathogens

Chairman’s Message
Shareholder Update